Literature DB >> 27868303

Fat-free mass index predicts survival in patients with idiopathic pulmonary fibrosis.

Osamu Nishiyama1, Ryo Yamazaki1, Hiroyuki Sano1, Takashi Iwanaga1, Yuji Higashimoto1, Hiroaki Kume1, Yuji Tohda1.   

Abstract

BACKGROUND AND
OBJECTIVE: Detailed body composition, such as fat-free mass, has not been examined in idiopathic pulmonary fibrosis (IPF). We investigated whether the fat-free mass index (FFMI), an index of lean body mass, predicted survival.
METHODS: Forty-four patients with IPF were enrolled in the study. Their body composition was assessed using direct segmental multi-frequency bioelectrical impedance analysis. The degree of correlation between variables of body composition and other variables such as forced vital capacity (FVC) and survival was examined.
RESULTS: There was a significant positive correlation between FFMI and FVC, diffusion capacity of the lung for carbon monoxide (DLCO ) and 6-min walk distance, and a significant negative correlation with age. However, there was no significant correlation between FFMI and percentage predicted FVC or DLCO , with the degree of correlation being similar to that observed for BMI. The mean observation period in the survival analysis was 837.5 ± 407.5 days. A univariate Cox proportional hazard model showed that several variables, but not BMI, were associated significantly with survival. FFMI (hazard ratio (HR): 0.64, 95% CI: 0.43-0.94, P = 0.02) and percentage predicted FVC (HR: 0.96, 95% CI: 0.93-0.99, P=0.008) were significant factors in a multivariate model.
CONCLUSION: We conclude that FFMI is a significant independent predictor of survival in patients with IPF.
© 2016 Asian Pacific Society of Respirology.

Entities:  

Keywords:  body composition; fat-free mass; idiopathic pulmonary fibrosis; survival

Mesh:

Substances:

Year:  2016        PMID: 27868303     DOI: 10.1111/resp.12941

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  10 in total

1.  Decreased peak expiratory flow rate associated with mortality in idiopathic pulmonary fibrosis: A preliminary report.

Authors:  Kohei Fujita; Hirotsugu Ohkubo; Akiko Nakano; Norihisa Takeda; Kensuke Fukumitsu; Satoshi Fukuda; Yoshihiro Kanemitsu; Takehiro Uemura; Tomoko Tajiri; Ken Maeno; Yutaka Ito; Tetsuya Oguri; Yoshiyuki Ozawa; Takayuki Murase; Akio Niimi
Journal:  Chron Respir Dis       Date:  2022 Jan-Dec       Impact factor: 3.115

2.  Serum creatinine/cystatin C ratio is a surrogate marker for sarcopenia in patients with idiopathic pulmonary fibrosis.

Authors:  Kohei Fujita; Hirotsugu Ohkubo; Akiko Nakano; Norihisa Takeda; Kensuke Fukumitsu; Satoshi Fukuda; Yoshihiro Kanemitsu; Takehiro Uemura; Tomoko Tajiri; Ken Maeno; Yutaka Ito; Tetsuya Oguri; Yoshiyuki Ozawa; Takayuki Murase; Akio Niimi
Journal:  BMC Pulm Med       Date:  2022-05-23       Impact factor: 3.320

Review 3.  Implications of low muscle mass across the continuum of care: a narrative review.

Authors:  Carla M Prado; Sarah A Purcell; Carolyn Alish; Suzette L Pereira; Nicolaas E Deutz; Daren K Heyland; Bret H Goodpaster; Kelly A Tappenden; Steven B Heymsfield
Journal:  Ann Med       Date:  2018-09-12       Impact factor: 4.709

Review 4.  Nutrition in Patients with Idiopathic Pulmonary Fibrosis: Critical Issues Analysis and Future Research Directions.

Authors:  Paola Faverio; Marialuisa Bocchino; Antonella Caminati; Alessia Fumagalli; Monica Gasbarra; Paola Iovino; Alessandra Petruzzi; Luca Scalfi; Alfredo Sebastiani; Anna Agnese Stanziola; Alessandro Sanduzzi
Journal:  Nutrients       Date:  2020-04-17       Impact factor: 5.717

5.  Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial.

Authors:  Silvia Perez-Bogerd; Wim Wuyts; Veronica Barbier; Heleen Demeyer; Alain Van Muylem; Wim Janssens; Thierry Troosters
Journal:  Respir Res       Date:  2018-09-20

6.  Systematic review and meta-analysis of lean mass and mortality: Rationale and study description.

Authors:  Ching-Lung Cheung; Grace Koon-Yee Lee; Philip Chun-Ming Au; Gloria Hoi-Yee Li; Marcus Chan; Hang-Long Li; Bernard Man-Yung Cheung; Ian Chi-Kei Wong; Victor Ho-Fun Lee; James Mok; Benjamin Hon-Kei Yip; Kenneth King-Yip Cheng; Chih-Hsing Wu
Journal:  Osteoporos Sarcopenia       Date:  2021-02-11

7.  Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study.

Authors:  Paola Faverio; Alessia Fumagalli; Sara Conti; Fabiana Madotto; Francesco Bini; Sergio Harari; Michele Mondoni; Tiberio Oggionni; Emanuela Barisione; Paolo Ceruti; Maria Chiara Papetti; Bruno Dino Bodini; Antonella Caminati; Angela Valentino; Stefano Centanni; Donatella Noè; Matteo Della Zoppa; Silvia Crotti; Marco Grosso; Samir Giuseppe Sukkar; Denise Modina; Marco Andreoli; Roberta Nicali; Giulia Suigo; Federica De Giacomi; Sara Busnelli; Elena Cattaneo; Lorenzo Giovanni Mantovani; Giancarlo Cesana; Alberto Pesci; Fabrizio Luppi
Journal:  ERJ Open Res       Date:  2022-03-07

8.  Relationship between body composition, exercise capacity and health-related quality of life in idiopathic pulmonary fibrosis.

Authors:  Felipe V C Machado; Ada E M Bloem; Tessa Schneeberger; Inga Jarosch; Rainer Gloeckl; Sandra Winterkamp; Frits M E Franssen; Andreas R Koczulla; Fabio Pitta; Martijn A Spruit; Klaus Kenn
Journal:  BMJ Open Respir Res       Date:  2021-10

9.  Treatment and Systemic Sclerosis Interstitial Lung Disease Outcome: The Overweight Paradox.

Authors:  Alexandra Nagy; Erik Palmer; Lorinc Polivka; Noemi Eszes; Krisztina Vincze; Eniko Barczi; Aniko Bohacs; Adam Domonkos Tarnoki; David Laszlo Tarnoki; György Nagy; Emese Kiss; Pal Maurovich-Horvat; Veronika Müller
Journal:  Biomedicines       Date:  2022-02-13

10.  Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis.

Authors:  Kohei Fujita; Hirotsugu Ohkubo; Akiko Nakano; Yuta Mori; Kensuke Fukumitsu; Satoshi Fukuda; Yoshihiro Kanemitsu; Takehiro Uemura; Tomoko Tajiri; Ken Maeno; Yutaka Ito; Tetsuya Oguri; Yoshiyuki Ozawa; Takayuki Murase; Akio Niimi
Journal:  Chron Respir Dis       Date:  2022 Jan-Dec       Impact factor: 3.115

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.